Trevi Therapeutics to Participate in Upcoming June Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Trevi Therapeutics (TRVI) PT Raised to $23 at Oppenheimer
June 2, 2025 4:03 PM EDTOppenheimer analyst Leland Gershall raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $23.00 (from $20.00) while maintaining a Outperform rating.
The analyst comments "Further detail to this morning's positive topline Phase 2b announcement per the company's webcast with KOL and slides... More
Trevi Therapeutics (TRVI) Falls to LOD, Down ~7pct, Raymond James: 'This is a clean win and Haduvio has now set the bar in IPF-CC'
June 2, 2025 12:18 PM EDTRaymond James analyst Ryan Deschner reiterated a Strong Buy rating and $29.00 price target on Trevi Therapeutics (NASDAQ: TRVI).
The analyst comments "Trevi reported statistically significant reductions on the 24-hr cough reduction primary endpoint in the Phase 2b CORAL study, including placebo-adjusted reductions >30% for all doses and a placebo-adjusted 43.3% reduction for the 108mg BID dose. This is a clean win and Haduvio has now... More
